key: cord-1026509-0fum4msj
authors: Meersseman, Philippe; Blondeel, Joris; De Vlieger, Greet; van der Merwe, Schalk; Monbaliu, Diethard
title: Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients
date: 2021-06-29
journal: Intensive Care Med
DOI: 10.1007/s00134-021-06445-8
sha: 69b99814078daf4ebce51c97fef05aef7af1585c
doc_id: 1026509
cord_uid: 0fum4msj

nan

The hallmark pneumonia of SARS-CoV-2 infection (coronavirus disease 2019, is often accompanied by important extra-pulmonary manifestations. Liver dysfunction occurs in up to 45% of patients and manifests predominantly as moderate transaminitis. Although the hepatic expression of angiotensin-converting-enzyme-2 (ACE2) receptor is largely restricted to cholangiocytes, reports of cholestatic injury have been rare [1] .

In the first 12 weeks of the pandemic, 3/114 COVID-19 patients admitted to our tertiary intensive care unit (ICU) developed a rapidly progressive cholestatic liver injury that persisted after the acute respiratory distress syndrome (ARDS) had resolved, and evolved to a condition reminiscent of secondary sclerosing cholangitis in critically ill patients (SSC-CIP), a rare but often fatal complication in patients receiving prolonged critical care [2] . During the same time period, a fourth patient with this condition was referred to our center (Fig. 1) .

The patients were male, aged 48-68, and required prolonged mechanical ventilation, renal support, and veno-venous extracorporeal membrane oxygenation (VV-ECMO, supplementary Table 1 ). Magnetic resonance cholangiopancreatography (MRCP) showed focal strictures in intrahepatic bile ducts with intraluminal sludge and casts, the radiological hallmark of SSC-CIP. Liver biopsies showed findings consistent with biliary obstruction, typical for SSC (supplementary Fig. 2 ). Patients 1 and 2 ultimately required liver transplantation because of refractory cholangitis with irreversible biliary damage: patient 1 is currently doing well but patient 2 died of post-transplant pneumonia and septic shock. Patient 3 experienced a milder form of SSC-CIP and is currently doing well, while patient 4 died as a result of a lethal hepatic haemorrhage.

With an estimated prevalence of 1/2000 (0.05%) ICU admissions, SSC-CIP was remarkably frequent with 3/114 ICU patients (2.6%) over 3 months and represented 3/74 (4.1%) of mechanically ventilated and 3/13 (23.1%) of VV-ECMO-treated patients [3] . COVID-19-specific disease and treatment factors may have precipitated biliary ischemia and cholangiopathy, including varying degrees of hemodynamic instability, high positive endexpiratory pressures reducing hepatosplanchnic blood flow, drug-induced bile duct injury by sedatives such as ketamine, parenteral nutrition, and the exaggerated proinflammatory cytokine storm that interferes with the biliary epithelium's physiological defense against hydrophobic bile salts [2, 4] .

Importantly, SARS-CoV-2 RNA and nucleo-capsid protein have been detected in the cholangiocytes and bile of patients with fatal COVID-19 pneumonia, suggesting that a direct cytopathic effect may occur [5] . Moreover, endothelialitis resulting in hypercoagulability and microthrombi deposition in the peribiliary vascular plexus may aggravate ischemia of the biliary epithelium.

This report aims to raise awareness about the risk for COVID-19 patients to develop severe cholestatic liver dysfunction reminiscent of SSC-CIP. As COVID-19 becomes better understood, more patients may recover from ARDS and require prolonged critical care with its associated risks. Our data-although from a small cohort-indicate a spectrum of severity, ranging from asymptomatic bile duct abnormalities to cholangiosepsis. Infamous for its bleak prognosis, early diagnosis with MRCP is critical. Whether mild forms confer a risk for secondary biliary cirrhosis is unknown. The outcome of liver transplantation for COVID-19-cholangiopathy remains to be determined, but a timely multidisciplinary evaluation is warranted. A direct causal role of SARS-CoV-2 in COVID-19-associated SSC-CIP is the subject of ongoing investigations.

(See figure on previous page.) Fig. 1 Temporal evolution of liver tests, treatments & MRCP images. For each individual patient (rows), the temporal evolution of liver enzymes, along with time points when critical diagnostic or treatment events occurred (left). Levels of gamma-glutamyltransferase (Gamma GT), alkaline phosphatase (ALP), aspartate transaminase (AST) and alanine transaminase (ALT) are projected on the left vertical axis and expressed as U/L, total bilirubin is projected on the right vertical axis and is expressed as mg/dl. VV-ECMO veno-venous extracorporeal membrane oxygenation, ERCP endoscopic retrograde cholangiopancreatography, MARS molecular absorbent recirculating system, LT liver transplantation. Cholestasis was defined as alkaline phosphatase > 1.5 times the upper limit. Also shown are a representative MRCP image for each patient (right) illustrating: in patient 1, diffuse beading of the intrahepatic biliary system (*); in patient 2 and 3, diffuse beading of the intrahepatic biliary ducts (*) and focal strictures on the left and right hepatic ducts (arrows); in patient 4, focal strictures on the right hepatic duct (arrows) and diminished arborisation of the intrahepatic biliary tree (#). All these findings are consistent with the diagnosis of 'Secondary Sclerosing Cholangitis in Critically Ill Patients' (SSC-CIP)

Extrapulmonary manifestations of COVID-19

Secondary sclerosing cholangitis in critically ill patients: an underdiagnosed entity

Intensive care unit acquired muscle weakness in COVID-19 patients

Secondary sclerosing cholangitis in critically ill patients: current perspectives

Hepatic vasculopathy and regenerative responses of the liver in fatal cases of COVID-19